Dutch-beta thalassemia: A rare mutation from India
Introduction: COVID-19 pandemic imposed challenges towards management of transfusion-dependent thalassemia patients (TDT). The need for regular blood transfusions and iron chelation therapy in these patients added further uncertainty about managing COVID-19 in this subset of patients. Aims: To descr...
Main Authors: | Nirali Sanghvi, Priyanka Aggarwal, Vineeta Singh, Vineeta Gupta |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-09-01
|
Series: | Pediatric Hematology Oncology Journal |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2468124522002339 |
Similar Items
-
Home isolation in transfusion-dependent thalassemia patients with SARS CoV2 infection: Experience from a developing country
by: Shruti Kakkar, et al.
Published: (2022-09-01) -
Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes
by: Ricchi P, et al.
Published: (2015-12-01) -
Adherence to Iron Chelation Therapy and Its Determinants
by: Sukhmani Sidhu, et al.
Published: (2021-01-01) -
Iron Chelator Drugs in Transfusion Dependent Thalassemia: a Review
by: M Hashemieh
Published: (2020-08-01) -
Use of Deferasirox Film-Coated Tablets in Pediatric Patients with Transfusion Dependent Thalassemia: A Single Center Experience
by: Alkistis Adramerina, et al.
Published: (2022-02-01)